MedPath
HSA Product

TROPHAMINE INJECTION 10%

Product approved by Health Sciences Authority (SG)

Basic Information

TROPHAMINE INJECTION 10%

INJECTION

Regulatory Information

SIN07846P

September 12, 1994

General Sale List

Therapeutic

INTRAVENOUS

August 10, 2023

June 4, 2025

XB05BA01

Company Information

B. BRAUN SINGAPORE PTE LTD

B. BRAUN SINGAPORE PTE LTD

Active Ingredients

GLYCINE

Strength: 0.36 g/100 ml

ISOLEUCINE

Strength: 0.82 g/100 ml

TAURINE

Strength: 0.025 g/100 ml

ARGININE

Strength: 1.2 g/100 ml

METHIONINE

Strength: 0.34 g/100 ml

LYSINE ACETATE EQV LYSINE

Strength: 0.82 g/100 ml

SERINE

Strength: 0.38 g/100 ml

TRYPTOPHAN

Strength: 0.2 g/100 ml

PHENYLALANINE

Strength: 0.48 g/100 ml

VALINE

Strength: 0.78 g/100 ml

L-GLUTAMIC ACID

Strength: 0.5 g/100 ml

THREONINE

Strength: 0.42 g/100 ml

ALANINE

Strength: 0.54 g/100 ml

PROLINE

Strength: 0.68 g/100 ml

LEUCINE

Strength: 1.4 g/100 ml

HISTIDINE

Strength: 0.48 g/100 ml

L-ASPARTIC ACID

Strength: 0.32 g/100 ml

Detailed Information

Contraindications

**CONTRAINDICATIONS** TrophAmine® is contraindicated in patients with untreated anuria, hepatic coma, inborn errors of amino acid metabolism, including those involving branched chain amino acid metabolism such as maple syrup urine disease and isovaleric acidemia, or hypersensitivity to one or more amino acids present in the solution.

Indication Information

**INDICATIONS AND USAGE** TrophAmine® is indicated for the nutritional support of infants (including those of low birth weight) and young pediatric patients requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with TrophAmine® is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young pediatric patients where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. See **WARNINGS, PRECAUTIONS, _Pediatric Use,_ AND DOSAGE AND ADMINISTRATION** – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. **_Central Venous Nutrition_** Central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted infants, or those requiring long-term parenteral nutrition. **_Peripheral Parenteral Nutrition_** For moderately catabolic or depleted patients in whom the central venous route is not indicated, diluted amino acid solutions mixed with 5–10% dextrose solutions may be infused by peripheral vein, supplemented, if desired, with fat emulsion. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).

© Copyright 2025. All Rights Reserved by MedPath